{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:05:04Z","timestamp":1747181104043,"version":"3.40.5"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"52","license":[{"start":{"date-parts":[[2022,12,30]],"date-time":"2022-12-30T00:00:00Z","timestamp":1672358400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12,30]]},"abstract":"<jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>In recent years, many clinical trials have used low-dose mifepristone to control uterine fibroids, some of which have achieved good results. However, according to the classic concept, long-term use of mifepristone could induce malignant transformation of the endometrium, and the effect of ultra-low-dose of mifepristone on uterine fibroids is still uncertain. Researchers are short on cases of uterine fibroids treated with mifepristone for long periods (more than a year).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>A 47-year-old woman went to the hospital because of anemia.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnoses:<\/jats:title>\n            <jats:p>The patient was diagnosed with uterine leiomyoma.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>The patient refused the suggestion of surgery, she was continuously treated with an ultra-low-dose (12.5\u2009mg per 5 days) of mifepristone monotherapy for 4 years.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>The uterine leiomyoma was stable, anemia and other symptoms disappeared, and the menstrual cycle, liver and kidney function, and tumor markers were normal.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>Judging from our case, long-term, ultra-low-dose mifepristone for uterine fibroids treatment was safe and more effective than conventional therapy.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000032413","type":"journal-article","created":{"date-parts":[[2022,12,30]],"date-time":"2022-12-30T13:04:57Z","timestamp":1672405497000},"page":"e32413","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Long-term use of ultra-low-dose mifepristone for uterine leiomyoma control and safety discussion: A case report"],"prefix":"10.1097","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2009-5011","authenticated-orcid":false,"given":"Guangdi","family":"Zhou","sequence":"first","affiliation":[{"name":"MOE-Shanghai Key Laboratory of Children's Environmental Health, Xinhua Hospital, Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8696-039X","authenticated-orcid":false,"given":"Qin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Shanghai Changhai Hospital, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1002\/ijc.27424","article-title":"MED12 mutations in uterine fibroids--their relationship to cytogenetic subgroups.","volume":"131","author":"Markowski","year":"2012","journal-title":"Int J Cancer"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1002\/ijc.28410","article-title":"Exomic landscape of MED12 mutation-negative and -positive uterine leiomyomas.","volume":"134","author":"M\u00e4kinen","year":"2014","journal-title":"Int J Cancer"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/his.12039","article-title":"Prevalence of MED12 mutations in uterine and extrauterine smooth muscle turnouts.","volume":"62","author":"Matsubara","year":"2013","journal-title":"Histopathology"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.humpath.2013.08.005","article-title":"MED12 exon 2 mutations in uterine and extrauterine smooth muscle.","volume":"45","author":"Schwetye","year":"2014","journal-title":"Hum Pathol"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1089\/gtmb.2010.0255","article-title":"Detection of somatic mutations and germline polymorphismsin mitoehondrial DNA of uterine fibroids patients.","volume":"15","author":"Shaik","year":"2011","journal-title":"Genet Test Mol Biomarkers"},{"key":"R6-20250504","first-page":"4910","article-title":"Study on regulation of p53 signal pathway by Chinese herbs for strengthening the body resistance and removing blood stasis in uterine leiomyoma model rats by Gene expression profiling.","volume":"5","author":"Li","year":"2010","journal-title":"Matern Child Health Care China"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.fertnstert.2007.01.093","article-title":"Etiology, symptomatology, and diagnosis of uterine myomas.","volume":"87","author":"Parker","year":"2007","journal-title":"Fertil Steril"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1055\/s-0030-1251483","article-title":"Cell-type specifc actions of progesterone receptor modulators in the regulation of uterine leiomyoma growth.","volume":"28","author":"Yoshida","year":"2010","journal-title":"Semin Reprod Med"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1093\/humupd\/dmm023","article-title":"Progesterone receptor modulators and the endometrium: changes and consequences.","volume":"13","author":"Farland","year":"2007","journal-title":"Hum Reprod Update"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1093\/humupd\/dmm023","article-title":"Progesterone receptor modulators and the endometrium: changes and consequences.","volume":"13","author":"Vannuccini","year":"2007","journal-title":"Hum Reprod Update"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0015-0282(16)57678-X","article-title":"Regression of uterine leiomyomata to the antiprogesterone RU486: dose-response effect.","volume":"64","author":"Murphy","year":"1995","journal-title":"Fertil Steril"},{"key":"R12-20250504","first-page":"1671","article-title":"Effects of long-term administration of low-dose mifepristone on endometrial morphology, function and estrogen and progesterone receptors.","volume":"8","author":"Zhu","year":"2004","journal-title":"Health Vocat Educ"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.humpath.2010.11.003","article-title":"Distinguishing features of endometrial pathology after exposure to the progesterone receptor modulator mifepristone.","volume":"42","author":"Fiscella","year":"2011","journal-title":"Hum Pathol"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0015-0282(16)57478-0","article-title":"Endometrial effects of long-term low-dose administration of RU486.","volume":"63","author":"Murphy","year":"1995","journal-title":"Fertil Steril"},{"key":"R15-20250504","first-page":"261","article-title":"National symposium on clinical application of mifepristone in obstetrics and gynecology.","volume":"34","author":"Weng","year":"1999","journal-title":"Chin Obstet Gynecol Mag"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1097\/AOG.0b013e31818aa930","article-title":"Mifepristone for the treatment of uterine leiomyomas: a randomized controlled trial.","volume":"112","author":"Esteve","year":"2008","journal-title":"Obstet Gynecol"},{"key":"R18-20250504","first-page":"51","article-title":"Mifepristone 5\u2009mg versus 10\u2009mg daily in the treatment of leiomyoma: randomized trial.","volume":"53","author":"Eisinger","year":"2010","journal-title":"Prog de Obstet y Ginecol"},{"key":"R19-20250504","first-page":"231","article-title":"Evolution of uterine leiomyoma after treatment with mifepristone: a randomized clinical trial.","volume":"53","author":"Esteve","year":"2010","journal-title":"Prog de Obstet y Ginecol"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ejogrb.2011.12.018","article-title":"Treatment of uterine myoma with 5 or 10\u2009mg mifepristone daily during 6 months, post-treatment evolution over 12 months: double-blind randomised clinical trial.","volume":"161","author":"Carbonell","year":"2012","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2147\/IJWH.S28103","article-title":"Mifepristone 2.5\u2009mg versus 5\u2009mg daily in the treatment of leiomyoma before surgery.","volume":"4","author":"Carbonell","year":"2012","journal-title":"Int J Womens Health"},{"key":"R22-20250504","first-page":"243","article-title":"Low-dose mifepristone for uterine leiomyomata.","volume":"101","author":"Eisinger","year":"2003","journal-title":"Obstet Gynecol"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jmig.2005.01.022","article-title":"Twelve month safety and efficacy of low-dose mifepristone for uterine myomas.","volume":"12","author":"Eisinger","year":"2005","journal-title":"J Minim Invasive Gynecol"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1097\/01.AOG.0000243776.23391.7b","article-title":"Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size: a randomized controlled trial.","volume":"108","author":"Fiscella","year":"2006","journal-title":"Obstet Gynecol"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1093\/humrep\/dep100","article-title":"Mifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trial.","volume":"24","author":"Engman","year":"2009","journal-title":"Hum Reprod"},{"key":"R26-20250504","first-page":"624","article-title":"Treatment of uterine leiomyoma by two different doses of mifepristone.","volume":"31","author":"Yang","year":"1996","journal-title":"Chin Obstet Gynecol Mag"},{"key":"R27-20250504","first-page":"490","article-title":"A clinical control study on the treatment of uterine leiomyoma with gonadotrophin releasing hormone agonist or mifepristone.","volume":"33","author":"Zeng","year":"1998","journal-title":"Chin Obstet Gynecol Mag"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ejogrb.2009.06.004","article-title":"Open-label study of ultra low-dose mifepristone for the treatment of uterine leiomyomata.","volume":"146","author":"Eisinger","year":"2009","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"R29-20250504","first-page":"649030","article-title":"Treatment of uterine myoma with 2.5 or 5\u2009mg mifepristone daily during 3 months with 9 months posttreatment followup: randomized clinical trial.","volume":"2013","author":"Carbonell","year":"2013","journal-title":"Obstet Gynecol"},{"key":"R30-20250504","first-page":"1673","article-title":"Analysis of the clinical effect of low-dose mifepristone in the treatment of hysteromyoma.","volume":"1","author":"Hu","year":"2012","journal-title":"J Yunnan Univ Nat Sci Ed"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/humrep\/deg022","article-title":"Effect of long-term treatment with low-dose mifepristone on the endometrium.","volume":"18","author":"Baird","year":"2003","journal-title":"Human Reprod"},{"key":"R32-20250504","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1210\/jc.2003-031945","article-title":"Low-dose mifepristone inhibits endometrial proliferation and up-regulates androgen receptor.","volume":"89","author":"Narvekar","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"R33-20250504","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/humrep\/12.1.124","article-title":"Effect of low daily doses of mifepristone on ovarian function and endometrial development.","volume":"12","author":"Danielsson","year":"1997","journal-title":"Human Reprod"},{"key":"R34-20250504","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1093\/humrep\/13.4.793","article-title":"Effects of long-term low-dose mifepristone on reproductive function in women.","volume":"13","author":"Croxatto","year":"1998","journal-title":"Human Reprod"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000032413","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T04:26:17Z","timestamp":1746332777000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000032413"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,30]]},"references-count":33,"journal-issue":{"issue":"52","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000032413","relation":{},"ISSN":["1536-5964"],"issn-type":[{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2022,12,30]]}}}